DR info

臨床試験数 : 23 / 薬物数 : 31 - (DrugBank : 8) / 標的遺伝子数 : 17 - 標的パスウェイ数 : 23

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

291844
   PTC Therapeutics, Inc.
      2010   Phase 2   EUCTR2009-016654-41-GB   Belgium;France;Italy;United Kingdom;
      2010   -   EUCTR2009-016654-41-FR   France;Italy;United Kingdom;
Ataluren
   PTC Therapeutics
      2010   Phase 2   NCT01141075   Belgium;France;Germany;Italy;Switzerland;United Kingdom;
   PTC Therapeutics, Inc.
      2010   Phase 2   EUCTR2009-016654-41-GB   Belgium;France;Italy;United Kingdom;
      2010   Phase 2   EUCTR2009-016654-41-BE   Belgium;France;Italy;Switzerland;United Kingdom;
      2010   -   EUCTR2009-016654-41-FR   France;Italy;United Kingdom;
BBP-671
   CoA Therapeutics, Inc., a BridgeBio company
      2021   Phase 1   NCT04836494   United States;
Bucladesine
   Ito Tetsuya
      2021   Phase 1-2   JPRN-jRCT2041210065   Japan;
Carbaglu
   Mendel Tuchman
      2012   Phase 2   NCT01599286   United States;
Carglumic Acid (Carbaglu®)
   National Taiwan University Hospital
      2019   -   NCT04284917   Taiwan;
Compound 1a
   PTC Therapeutics, Inc.
      2010   Phase 2   EUCTR2009-016654-41-GB   Belgium;France;Italy;United Kingdom;
      2010   -   EUCTR2009-016654-41-FR   France;Italy;United Kingdom;
HLB-001
   LogicBio Therapeutics, Inc.
      2021   Phase 1/Phase 2   NCT04581785   Saudi Arabia;United States;
HST5040
   HemoShear Therapeutics
      2021   Phase 2   NCT04732429   United States;
MRNA-3704
   ModernaTX, Inc.
      2019   Phase 1;Phase 2   EUCTR2019-001061-32-GB   United Kingdom;United States;
      2019   Phase 1/Phase 2   NCT03810690   United States;
MRNA-3705
   ModernaTX, Inc.
      2021   Phase 1/Phase 2   NCT04899310   Canada;United Kingdom;
PTC-0161480
   PTC Therapeutics, Inc.
      2010   Phase 2   EUCTR2009-016654-41-GB   Belgium;France;Italy;United Kingdom;
      2010   -   EUCTR2009-016654-41-FR   France;Italy;United Kingdom;
PTC-124
   PTC Therapeutics, Inc.
      2010   Phase 2   EUCTR2009-016654-41-GB   Belgium;France;Italy;United Kingdom;
      2010   -   EUCTR2009-016654-41-FR   France;Italy;United Kingdom;
PTC-C124
   PTC Therapeutics, Inc.
      2010   Phase 2   EUCTR2009-016654-41-GB   Belgium;France;Italy;United Kingdom;
      2010   -   EUCTR2009-016654-41-FR   France;Italy;United Kingdom;
PTC124
   PTC THERAPEUTICS, INC.
      2010   -   EUCTR2009-016654-41-IT   France;Italy;United Kingdom;
   PTC Therapeutics, Inc.
      2010   Phase 2   EUCTR2009-016654-41-GB   Belgium;France;Italy;United Kingdom;
      2010   Phase 2   EUCTR2009-016654-41-BE   Belgium;France;Italy;Switzerland;United Kingdom;
      2010   -   EUCTR2009-016654-41-FR   France;Italy;United Kingdom;
RPS 2505
   PTC Therapeutics, Inc.
      2010   Phase 2   EUCTR2009-016654-41-GB   Belgium;France;Italy;United Kingdom;
      2010   -   EUCTR2009-016654-41-FR   France;Italy;United Kingdom;